[ad_1] LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in […]

[ad_1] BIZENGRI® is the first and only FDA-approved therapy specifically for patients with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) who harbor NRG1 gene fusions1 NRG1 gene fusions are best detected by […]